Double maintains 1 strategies that include ARVN - Arvinas, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMNM | 42.51% | $825.75M | -40.69% | 0.00% |
CRBU | 40.24% | $109.75M | -40.10% | 0.00% |
CRSP | 40.14% | $3.59B | -35.96% | 0.00% |
TECH | 39.47% | $8.08B | -33.45% | 0.62% |
ITW | 39.35% | $72.26B | +2.84% | 2.40% |
GMAB | 39.33% | $13.91B | -15.47% | 0.00% |
CNI | 39.30% | $65.54B | -15.20% | 2.38% |
RWT | 38.93% | $768.09M | -10.96% | 11.92% |
AVO | 38.70% | $813.52M | +9.09% | 0.00% |
ASAN | 38.50% | $3.33B | +6.16% | 0.00% |
ARCT | 38.48% | $337.38M | -59.95% | 0.00% |
RMR | 37.91% | $273.75M | -30.36% | 11.10% |
OCSL | 37.72% | - | - | 14.09% |
NDSN | 37.60% | $12.39B | -5.78% | 1.07% |
GRWG | 37.54% | $74.37M | -51.55% | 0.00% |
CAR | 37.43% | $4.47B | +13.72% | 0.00% |
NLY | 37.31% | $11.69B | -2.82% | 13.69% |
XYL | 37.17% | $30.91B | -9.71% | 1.20% |
DX | 37.17% | $1.32B | +5.12% | 14.21% |
BIIB | 37.09% | $19.50B | -42.31% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 46.11% | $5.23B | 0.45% |
XPH | 45.65% | $153.36M | 0.35% |
XBI | 45.26% | $4.89B | 0.35% |
GNOM | 43.02% | $44.34M | 0.5% |
BBH | 42.94% | $334.99M | 0.35% |
PBE | 42.63% | $229.19M | 0.58% |
IWC | 41.88% | $813.58M | 0.6% |
PINK | 41.32% | $131.18M | 0.5% |
KBWD | 41.01% | $397.13M | 4.93% |
FBT | 40.83% | $1.05B | 0.54% |
IHE | 39.87% | $568.11M | 0.39% |
RIET | 39.36% | $90.73M | 0.5% |
VHT | 39.35% | $15.31B | 0.09% |
IYT | 39.10% | $687.17M | 0.39% |
SRET | 39.09% | $182.46M | 0.59% |
FHLC | 39.01% | $2.45B | 0.084% |
MORT | 38.71% | $299.11M | 0.42% |
SCHD | 38.60% | $69.32B | 0.06% |
PEY | 38.53% | $1.11B | 0.53% |
ARKG | 38.43% | $980.60M | 0.75% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
HTAB | 0.41% | $409.06M | 0.39% |
JMST | -0.48% | $3.84B | 0.18% |
GBIL | -0.52% | $6.05B | 0.12% |
SOYB | -0.56% | $25.66M | 0.22% |
XONE | 0.64% | $634.70M | 0.03% |
STOT | -0.67% | $235.94M | 0.45% |
DBE | 0.68% | $48.80M | 0.77% |
SPTS | 0.89% | $5.78B | 0.03% |
UUP | -1.01% | $209.44M | 0.77% |
UGA | -1.02% | $72.57M | 0.97% |
KMLM | 1.22% | $192.65M | 0.9% |
CORN | 1.25% | $47.42M | 0.2% |
KCCA | 1.36% | $93.93M | 0.87% |
BIL | -1.45% | $44.07B | 0.1356% |
IBMN | 1.48% | $447.67M | 0.18% |
UTWO | 1.56% | $374.41M | 0.15% |
WEAT | 1.66% | $121.10M | 0.28% |
CMBS | 1.76% | $438.36M | 0.25% |
TFLO | 1.83% | $6.97B | 0.15% |
UDN | 2.04% | $145.23M | 0.78% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -24.13% | $153.01M | 0.85% |
TAIL | -22.05% | $107.77M | 0.59% |
BTAL | -20.67% | $298.87M | 1.43% |
TPMN | -12.56% | $30.67M | 0.65% |
XHLF | -9.91% | $1.64B | 0.03% |
IVOL | -7.83% | $358.39M | 1.02% |
ULST | -6.64% | $663.99M | 0.2% |
UNG | -5.69% | $372.51M | 1.06% |
FTSD | -4.51% | $228.13M | 0.25% |
CTA | -3.70% | $1.09B | 0.76% |
USDU | -2.83% | $165.88M | 0.5% |
FXE | -2.14% | $547.46M | 0.4% |
BIL | -1.45% | $44.07B | 0.1356% |
UGA | -1.02% | $72.57M | 0.97% |
UUP | -1.01% | $209.44M | 0.77% |
STOT | -0.67% | $235.94M | 0.45% |
SOYB | -0.56% | $25.66M | 0.22% |
GBIL | -0.52% | $6.05B | 0.12% |
JMST | -0.48% | $3.84B | 0.18% |
HTAB | 0.41% | $409.06M | 0.39% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PAY | -14.95% | $4.41B | +81.23% | 0.00% |
LITB | -6.41% | $21.77M | -74.81% | 0.00% |
EXK | -5.85% | $1.44B | +38.94% | 0.00% |
TRVG | -5.69% | $96.56M | +91.82% | 0.00% |
TXNM | -5.59% | $5.26B | +50.82% | 2.81% |
BTCT | -5.33% | $21.81M | +56.22% | 0.00% |
CPSH | -5.08% | $39.37M | +58.02% | 0.00% |
NEO | -4.35% | $1.01B | -44.31% | 0.00% |
STG | -4.11% | $32.24M | -0.16% | 0.00% |
BVS | -3.71% | $445.26M | -1.03% | 0.00% |
PSQH | -3.56% | $107.02M | -32.86% | 0.00% |
FMTO | -3.51% | $5.10K | -99.92% | 0.00% |
DFDV | -3.25% | $380.05M | +2,345.35% | 0.00% |
NTGR | -3.21% | $858.61M | +94.33% | 0.00% |
MYRG | -3.17% | $2.57B | +12.73% | 0.00% |
AIFU | -2.71% | $3.36B | 0.00% | 0.00% |
DRD | -2.69% | $1.21B | +68.55% | 1.94% |
ZCMD | -2.68% | $26.26M | -13.33% | 0.00% |
CYD | -2.45% | $718.48M | +121.39% | 1.85% |
K | -2.29% | $28.31B | +38.89% | 2.82% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
XGN | 0.04% | $158.67M | +268.53% | 0.00% |
XPEV | -0.06% | $15.86B | +173.13% | 0.00% |
BVN | -0.18% | $4.21B | -2.87% | 0.00% |
TEVA | -0.18% | $19.85B | +0.58% | 0.00% |
ETR | -0.22% | $35.39B | +53.04% | 4.26% |
HIHO | 0.23% | $7.75M | -16.98% | 3.98% |
IAG | 0.27% | $4.20B | +100.82% | 0.00% |
PRPO | -0.27% | $16.74M | +87.63% | 0.00% |
VHC | 0.35% | $37.77M | +135.71% | 0.00% |
BTU | 0.37% | $1.68B | -39.96% | 2.27% |
NIO | 0.40% | $7.27B | -15.96% | 0.00% |
TEF | -0.50% | $29.51B | +15.71% | 5.96% |
EQT | 0.50% | $32.31B | +32.38% | 1.15% |
VSTA | -0.58% | $331.23M | +31.32% | 0.00% |
BE | 0.60% | $5.23B | +47.16% | 0.00% |
LQDT | 0.60% | $759.91M | +23.55% | 0.00% |
PODD | 0.63% | $21.27B | +50.62% | 0.00% |
FMS | -0.66% | $16.66B | +32.05% | 2.83% |
HUSA | -0.67% | $8.56M | -56.67% | 0.00% |
EDSA | 0.69% | $13.06M | -58.48% | 0.00% |
Finnhub
NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. . Such investors are advised to contact Danielle Peyton...
Yahoo
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of
Finnhub
By Colin Kellaher Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor...
Finnhub
Arvinas, Inc. announced the submission of a New Drug Application to the U.S. Food and Drug Administration with its partner Pfizer Inc. for vepdegestrant for the treatment of patients with...
Yahoo
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma – NEW HAVEN, Conn., June 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs base
Finnhub
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome
Current Value
$7.611 Year Return
Current Value
$7.611 Year Return